Cullinan Oncology to Participate in the 41st Annual Canaccord Genuity Growth Conference

CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) announced today that it will be participating in the 41^st Annual Canaccord Genuity Growth Conference from August 10^th to August 12^th, 2021.

Jeff Trigilio, Cullinan’s Chief Financial Officer, will be presenting on Thursday, August 12^th at 4:00pm ET. The presentation will be accessible through the Canaccord conference portal.

Event: Canaccord Genuity Growth Conference
Date: Thursday, August 12^th
Time: 4:00pm ET
Location: Virtual

Management will also be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with Cullinan’s management should contact their Canaccord representative.

About Cullinan Oncology

Cullinan Oncology is a biopharmaceutical company that strives to deliver results for our various stakeholders through disciplined capital allocation, decisive action, prudent risk taking and creative business development. We seek to drive shareholder returns by focusing on the patient. The Company’s strategy is to build a diversified pipeline of targeted and immuno-oncology therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes. Learn more about Cullinan at www.cullinanoncology.com.

Contacts:

Investor Relations
investors@cullinanoncology.com

Jeff Trigilio
+1 617.410.4650
jtrigilio@cullinanoncology.com